Investment in digital health is growing rapidly and has cumulatively reached $15.5bn in the US alone. However, much of this growth has been characterized by fragmentation for pharmaceutical companies. Despite iOS and Android hosting over 165,000 health apps, more than 48% of pharmaceutical company published apps do not have a single user review. It is little wonder, therefore, that a recent study has highlighted that only 13% of pharmaceutical leaders are satisfied with their current digital activities.
Currently, 82% of mobile apps have just one or two functions which only allow them to support one specific part of the pharmaceutical value chain. However, digital technology, when properly...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?